button bars forest bayes pooled summary circles
 
deaths (OS)

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus cabozantinib
atezolizumab plus cabozantinib vs. cabozantinib 1 certainty unassessable-6%
versus everolimus
nivolumab alone vs. everolimus 1 certainty unassessablestatistically conclusive-25%

 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons